United Therapeutics (UTHR) COO exercises RSUs; 14,706 shares withheld for taxes
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp President and COO Michael Benkowitz reported routine equity compensation activity involving restricted stock units and common shares. On March 15, 2026, a trust associated with him exercised restricted stock units that each convert into one share of common stock, resulting in 33,382 shares of common stock held indirectly by the trust.
Of these shares, 14,706 shares of common stock were withheld by United Therapeutics to satisfy tax obligations upon vesting, a non-market disposition that does not represent an open-market sale. Following these transactions, the filing shows 19,046 shares held indirectly by the trust and 2,710 shares held directly, which includes 62 shares acquired earlier under the company’s employee stock purchase plan.
Positive
- None.
Negative
- None.
Insights
Routine RSU vesting and tax withholding with modest net share increase.
The filing shows a trust associated with Michael Benkowitz, President and COO of UNITED THERAPEUTICS Corp, exercising restricted stock units into 33,382 shares of common stock on March 15, 2026. Each restricted stock unit converts into one share after vesting, reflecting standard equity compensation mechanics.
The company withheld 14,706 shares at a price of $536.12 per share to cover tax liabilities, coded as F transactions. This is a tax-withholding disposition rather than an open-market sale, so it carries limited signaling value about management’s view of the stock.
After these entries, the trust holds 19,046 shares indirectly, and Benkowitz holds 2,710 shares directly, including 62 acquired under the employee stock purchase plan on March 4, 2026. With no remaining derivative positions shown and no open-market buying or selling, this appears to be routine compensation-related activity, not a thesis-changing event.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 17,790 | $0.00 | -- |
| Exercise | Restricted Stock Units | 15,592 | $0.00 | -- |
| Exercise | Common Stock | 17,790 | $0.00 | -- |
| Exercise | Common Stock | 15,592 | $0.00 | -- |
| Tax Withholding | Common Stock | 7,837 | $536.12 | $4.20M |
| Tax Withholding | Common Stock | 6,869 | $536.12 | $3.68M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units. Includes 62 shares of common stock acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan. Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.
